874902-19-9

874902-19-9 structure

Name: LY2183240
Chemical Name: N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide
CAS Number: 874902-19-9
Molecular Formula: C₁₇H₁₇N₅O
Molecular Weight: 307.350
Catalog: Signaling Pathways Metabolic Enzyme/Protease FAAH
Create Date: 2018-12-31 12:47:06
Modify Date: 2025-08-25 20:18:50
LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). LY2183240 inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). IC50: 270 pM (anandamide uptake); 12.4 nM (FAAH)Target: FAAH; Anandamide uptakeFollowing i.p. administration in rats, LY2183240 increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain.

Name	N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide
Synonyms	5-(4-Biphenylylmethyl)-N,N-dimethyl-1H-tetrazole-1-carboxamide LY-2183240 HMS3269E15 1H-Tetrazole-1-carboxamide 1H-Tetrazole-1-carboxamide, 5-([1,1'-biphenyl]-4-ylmethyl)-N,N-dimethyl- 5-(Biphenyl-4-ylmethyl)-N,N-dimethyl-1H-tetrazole-1-carboxamide LY2183240

Description	LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). LY2183240 inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). IC50: 270 pM (anandamide uptake); 12.4 nM (FAAH)Target: FAAH; Anandamide uptakeFollowing i.p. administration in rats, LY2183240 increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> FAAH Signaling Pathways >> Neuronal Signaling >> FAAH Research Areas >> Neurological Disease
References	[1]. Dickason-Chesterfield AK, et al. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):407-23. [2]. Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc. 2006 Aug 2;128(30):9699-704. [3]. Maione S, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol. 2008 Nov;155(5):775-82. [4]. Pelorosso FG, et al. The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. Eur J Pharmacol. 2009 Jan 5;602(1):176-9. [5]. Powers MS, et al. Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. Psychopharmacology (Berl). 2010 Dec;212(4):571-83. [6]. Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. Eur J Pain. 2017 May;21(5):804-814.

Density	1.2±0.1 g/cm3
Boiling Point	506.1±53.0 °C at 760 mmHg
Melting Point	87-88ºC
Molecular Formula	C₁₇H₁₇N₅O
Molecular Weight	307.350
Flash Point	259.9±30.9 °C
Exact Mass	307.143311
PSA	63.91000
LogP	2.15
Vapour Pressure	0.0±1.3 mmHg at 25°C
Index of Refraction	1.640
Storage condition	2-8℃

Risk Phrases	22

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

874902-19-9	1040666-00-9
690214-20-1	1037161-39-9
1094318-44-1	1152504-13-6
946203-04-9	1181479-10-6
946357-33-1	921548-07-4
859393-09-2